# Chlorpromazine and Standard of Care in Glioblastoma

> **NCT05190315** · PHASE1 · COMPLETED · sponsor: **Mohammed Milhem** · enrollment: 10 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Chlorpromazine
- **DRUG:** Temozolomide
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT05190315
- **Lead sponsor:** Mohammed Milhem
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-28
- **Primary completion:** 2023-04-25
- **Final completion:** 2024-07-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190315, "Chlorpromazine and Standard of Care in Glioblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05190315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*